Orphan Designation Removals To Be Revealed By FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
List will include whether a designation was lost, but not why, FDA says in final rule clarifying and updated 1992 orphan drug regulations.
You may also be interested in...
Targeted Therapies On FDA’s Orphan Designation Radar
As personalized medicine continues to grow, FDA is watching to see if there is a rise in orphan designations for products targeting a “smaller slice” of a common disease.
Orphan Disclosures Could Increase Under Tweaks Proposed By FDA
Agency considering whether to tell public if sponsors have submitted annual product development reports as part of proposed rule clarifying portions of 1992 Orphan Drug Regulations.
User Fee Discussions Include Funding Parts Of FDA Regulatory Science Plan
Commissioner Margaret Hamburg’s plans to improve regulatory science at FDA could benefit from application user fees, based on PDUFA negotiations.